Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

被引：0
|
作者：
Flaherty, Lawrence E.
Moon, James
Atkins, Michael B.
Tuthill, Ralph
Thompson, John A.
Vetto, John T.
Haluska, Frank G.
Pappo, Alberto S.
Sosman, Jeffrey Alan
Redman, Bruce G.
Ribas, Antoni
Kirkwood, John M.
Sondak, Vernon K.
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Seattle Canc Care Alliance, Seattle, WA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] ARIAD Pharmaceut, Cambridge, MA USA
[8] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[9] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[10] Univ Michigan, Ann Arbor, MI 48109 USA
[11] Univ Calif Los Angeles, Los Angeles, CA USA
[12] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[13] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
    Brandberg, Y.
    Aamdal, S.
    Bastholt, L.
    Hernberg, M.
    Stierner, U.
    von der Maase, H.
    Hansson, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (13) : 2012 - 2019
  • [42] A prospective randomized study of CHOP versus CHOP plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study
    Giles, FJ
    Shan, JQ
    Advani, SH
    Akan, H
    Aydogdu, I
    Aziz, Z
    Azim, HA
    Bapsy, PP
    Buyukkececi, F
    Chaimongkol, B
    Chen, PM
    Cheong, SK
    Ferhanoglu, B
    Hamza, R
    Khalid, HM
    Intragumtornchai, T
    Kim, SW
    Kim, SY
    Koc, H
    Kumar, L
    Kumar, R
    Lei, KI
    Lekhakula, A
    Muthalib, A
    Patel, M
    Poovalingam, VP
    Prayoonwiwat, W
    Rana, F
    Reksodiputro, AH
    Ruff, P
    Sagar, TG
    Schwarer, AP
    Song, HS
    Suh, CW
    Suharti, C
    Supindiman, I
    Tee, GY
    Thamprasit, T
    Villalon, AH
    Wickham, NR
    Wong, JE
    Yalcin, A
    Jootar, S
    LEUKEMIA & LYMPHOMA, 2000, 40 (1-2) : 95 - 103
  • [43] Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol [ISRCTN62866759]
    HP Knaebel
    A Märten
    J Schmidt
    K Hoffmann
    C Seiler
    K Lindel
    H Schmitz-Winnenthal
    S Fritz
    T Herrmann
    H Goldschmidt
    R Krempien
    U Mansmann
    J Debus
    V Diehl
    MW Büchler
    BMC Cancer, 5
  • [44] Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients
    Weichenthal, Michael
    Chiarion-Sileni, Vanna
    Hauschild, Axel
    Del Bianco, Paola
    Trefzer, Uwe
    Guida, Michele
    Enk, Alexander
    Romanini, Antonella
    Loquai, Carmen
    Ridolfi, Ruggero
    Schadendorf, Dirk
    Mandala, Mario
    Koller, Josef
    Silvestri, Barbara
    Gogas, Helen
    Medici, Michele
    Dummer, Reinhard
    De Salvo, Gian Luca
    Mohr, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat
    Pagel, John M.
    Othus, Megan
    Garcia-Manero, Guillermo
    Fang, Min
    Radich, Jerald P.
    Rizzieri, David A.
    Marcucci, Guido
    Strickland, Stephen A.
    Litzow, Mark
    Savoie, Mary Lynn
    Spellman, Stephen R.
    Confer, Dennis L.
    Chell, Jeffrey
    Brown, Maria
    Medeiros, Bruno C.
    Sekeres, Mikkael A.
    Lin, Tara L.
    Uy, Geoffrey L.
    Powell, Bayard L.
    Kolitz, Jonathan E.
    Larson, Richard A.
    Stone, Richard M.
    Claxton, David F.
    Essell, James
    Luger, Selina
    Mohan, Sanjay R.
    Moseley, Anna
    Erba, Harry P.
    Appelbaum, Frederick R.
    BLOOD, 2016, 128 (22)
  • [46] Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609.
    Tarhini, Ahmad A.
    Zheng, Yue
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma
    Cohen, Gary Irvin
    Sondak, Vernon K.
    Kirkwood, John M.
    Wagner, Lynne, I
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy
    McMasters, Kelly M.
    Egger, Michael E.
    Edwards, Michael J.
    Ross, Merrick I.
    Reintgen, Douglas S.
    Noyes, R. Dirk
    Martin, Robert C. G., II
    Goydos, James S.
    Beitsch, Peter D.
    Urist, Marshall M.
    Ariyan, Stephan
    Sussman, Jeffrey J.
    Davidson, B. Scott
    Gershenwald, Jeffrey E.
    Hagendoorn, Lee J.
    Stromberg, Arnold J.
    Scoggins, Charles R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1079 - +
  • [48] Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma CapRI:: study protocol [ISRCTN62866759] -: art. no. 37
    Knaebel, HP
    Märten, A
    Schmidt, J
    Hoffmann, K
    Seiler, C
    Lindel, K
    Schmitz-Winnenthal, H
    Fritz, S
    Herrmann, T
    Goldschmidt, H
    Mansmann, U
    Debus, J
    Diehl, V
    Büchler, MW
    BMC CANCER, 2005, 5 (1)
  • [49] Relapse-free and overall survival are significantly prolonged by high-dose IFN alpha 2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenics) for high-risk resected stage IIB-III melanoma: Results of the Intergroup Phase III study E1694/S9512/C503801.
    Kirkwood, JM
    Ibrahim, J
    Sondak, VK
    Sosman, JA
    Ernstoff, MS
    ANNALS OF ONCOLOGY, 2000, 11 : 4 - 4
  • [50] High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
    Kirkwood, JM
    Ibrahim, JG
    Sosman, JA
    Sondak, VK
    Agarwala, SS
    Ernstoff, MS
    Rao, U
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) : 2370 - 2380
12345